Human Mantle Cell Lymphoma Peripheral Blood Mononuclear Cells (Relapsed/Refactory)

Description

Human Mantle Cell Lymphoma Peripheral Blood Mononuclear Cells (Relapsed/Refractory) are isolated from the peripheral blood of patients with relapsed or refractory mantle cell lymphoma (MCL). Morphological assessment reveals a predominant population of atypical small lymphocytes. Immunophenotypically, these cells exhibit characteristic MCL markers, including diffuse expression of cyclin D1 (CCND1) and CD5, which are essential for diagnostic confirmation. The defining genetic alteration in these cells is the t(11;14)(q13;q32) chromosomal translocation, resulting in dysregulated cyclin D1 overexpression and subsequent cell cycle dysregulation. Additionally, these cells demonstrate constitutive activation of the B cell receptor (BCR) signaling pathway, promoting malignant B cell survival through sustained stimulation of downstream effectors, including the PI3K/AKT and MAPK cascades. In advanced research and clinical evaluation, these specimens are widely used to investigate therapeutic resistance mechanisms, assess emerging treatment strategies, support PBMC-based analyses, and generate clinically relevant data for relapsed or refractory mantle cell lymphoma.